Director Susan Knight purchased $102,228 worth of shares at $9.29, marking the largest insider purchase in the company's history. This significant buy signals confidence in the stock's trajectory as the company advances its pivotal clinical trial.
Price context
The stock has surged 56.14% over the last 30 days, trading at $9.665, which is 4.54% below its 52-week high of $10.125. The stock is up 103.9% over the last year, indicating strong momentum despite being slightly off its recent highs.
Catalysts to watch
- •Q1 earnings on May 12, 2026: The company reported operational progress and a $320 million capital raise during the March 2026 quarter.
- •US Medicare reimbursement eligibility secured on May 7, 2026: This milestone allows for patient recruitment and treatment in the US for the PARADIGM Trial.
- •Board expansion on May 13, 2026: The addition of Susan Knight and Stephen Denaro to the board strengthens the company's leadership as it advances its heart valve strategy.
Risks
- •High short interest of 10.49%: The significant float sold short suggests potential volatility and skepticism regarding the company's path to profitability.
- •Unprofitable operations: The company is currently burning cash, as noted in the May 13, 2026 article, which could pressure the stock if capital raises do not materialize.
AI-generated context from public data. Not investment advice. Verify before trading.